How many organs could you donate and remain alive? How many planet Earths could fit inside the Sun? How high is a giraffe's blood pressure? Why is the sea blue? To find out, Ask The Naked Scientists!
…
continue reading
内容由Jon Chee提供。所有播客内容(包括剧集、图形和播客描述)均由 Jon Chee 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Player FM -播客应用
使用Player FM应用程序离线!
使用Player FM应用程序离线!
🧬 Doug Drysdale - Cybin - Part 3 | Jumping from BD to M&A | Leveraging Debt for Strategic Acquisitions | The Importance of Cultural Fit in Successful Deals | Making an Impact at Norwich, Alvogen, & Pernix Therapeutics
Manage episode 437654496 series 3461709
内容由Jon Chee提供。所有播客内容(包括剧集、图形和播客描述)均由 Jon Chee 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.
Part 3 of 4.
Part 3 of 4.
My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics.
Doug is an experienced investor, Corporate Director and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During his 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised and invested around $4 billion of both public and private capital.
Before Cybin, Doug was Commercial Products Manager at DuPont Merck, Director of BD at Elan, VP of M&A at Actavis Group, CEO of Norwich Pharmaceuticals and Alvogen, CEO of Pernix Therapeutics, and CEO of Tedor Pharma. His extensive background as a seasoned executive, investor, and turn-around specialist gives him a wide range of experiences that founders can learn from.
Join us this week and hear about:
- Doug’s transition from BD to leading M&A at Actavis
- His insights on leveraging debt for acquisitions
- The importance of cultural fit in successful deals
- Doug’s strategic acquisitions at Actavis and the turnaround at Norwich Pharmaceuticals & Alvogen
- His challenges and successes at Pernix Therapeutics, the first public company Doug worked for
Please enjoy my conversation with Doug Drysdale.
Timestamps:
00:28 Intro
01:48 How to get into M&A as a scientist; what makes a successful M&A transaction?
05:19 Doug’s experience raising credit facilities to support M&A activity
07:46 Memorable challenges and triumphs at Actavis
12:24 How do you find good investment opportunities? Things to keep an eye out for
14:36 Doug’s move from Actavis to Norwich Pharmaceuticals and Alvogen
18:10 Growth strategies at Norwich/Alvogen: M&A and Licensing
19:14 Key lessons and takeaways from Doug’s time at Norwich/Alvogen; the importance of people and cultural fits
24:33 Turning things around with Pernix Therapeutics, a public company
26:50 Outro
Find Our Guest, Doug Drysdale, at these links:
Find Our Host, Jon Chee, at these links:
Social & Website
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Podcast Website: https://www.thebiotechstartupspodcast.com/
Enriched Notes:
Topics Mentioned:
Norwich Pharmaceuticals: https://en.wikipedia.org/wiki/Norwich_Pharma_Services
Alvogen: https://www.alvogen.com/
Debt Financing: https://www.excedr.com/blog/lease-financing-vs-debt-financing
Credit Facility: https://www.investopedia.com/terms/c/creditfacility.asp
Credit facilities for M&A activity: https://cpcp.ca/opinion/6-common-debt-financing-options-in-ma/
M&A Activity in Life Sciences: https://www.techtarget.com/pharmalifesciences/answer/Understanding-the-Value-of-Mergers-and-Acquisitions-in-Life-Sciences
IP Assets in Life Sciences: https://www.excedr.com/resources/intellectual-property-rights-for-biotechs
Sales and Marketing Strategies for Startups: https://www.excedr.com/blog/marketing-sales-strategies-for-biotechs
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
79集单集
Manage episode 437654496 series 3461709
内容由Jon Chee提供。所有播客内容(包括剧集、图形和播客描述)均由 Jon Chee 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.
Part 3 of 4.
Part 3 of 4.
My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics.
Doug is an experienced investor, Corporate Director and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During his 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised and invested around $4 billion of both public and private capital.
Before Cybin, Doug was Commercial Products Manager at DuPont Merck, Director of BD at Elan, VP of M&A at Actavis Group, CEO of Norwich Pharmaceuticals and Alvogen, CEO of Pernix Therapeutics, and CEO of Tedor Pharma. His extensive background as a seasoned executive, investor, and turn-around specialist gives him a wide range of experiences that founders can learn from.
Join us this week and hear about:
- Doug’s transition from BD to leading M&A at Actavis
- His insights on leveraging debt for acquisitions
- The importance of cultural fit in successful deals
- Doug’s strategic acquisitions at Actavis and the turnaround at Norwich Pharmaceuticals & Alvogen
- His challenges and successes at Pernix Therapeutics, the first public company Doug worked for
Please enjoy my conversation with Doug Drysdale.
Timestamps:
00:28 Intro
01:48 How to get into M&A as a scientist; what makes a successful M&A transaction?
05:19 Doug’s experience raising credit facilities to support M&A activity
07:46 Memorable challenges and triumphs at Actavis
12:24 How do you find good investment opportunities? Things to keep an eye out for
14:36 Doug’s move from Actavis to Norwich Pharmaceuticals and Alvogen
18:10 Growth strategies at Norwich/Alvogen: M&A and Licensing
19:14 Key lessons and takeaways from Doug’s time at Norwich/Alvogen; the importance of people and cultural fits
24:33 Turning things around with Pernix Therapeutics, a public company
26:50 Outro
Find Our Guest, Doug Drysdale, at these links:
Find Our Host, Jon Chee, at these links:
Social & Website
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Podcast Website: https://www.thebiotechstartupspodcast.com/
Enriched Notes:
Topics Mentioned:
Norwich Pharmaceuticals: https://en.wikipedia.org/wiki/Norwich_Pharma_Services
Alvogen: https://www.alvogen.com/
Debt Financing: https://www.excedr.com/blog/lease-financing-vs-debt-financing
Credit Facility: https://www.investopedia.com/terms/c/creditfacility.asp
Credit facilities for M&A activity: https://cpcp.ca/opinion/6-common-debt-financing-options-in-ma/
M&A Activity in Life Sciences: https://www.techtarget.com/pharmalifesciences/answer/Understanding-the-Value-of-Mergers-and-Acquisitions-in-Life-Sciences
IP Assets in Life Sciences: https://www.excedr.com/resources/intellectual-property-rights-for-biotechs
Sales and Marketing Strategies for Startups: https://www.excedr.com/blog/marketing-sales-strategies-for-biotechs
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
79集单集
Alle episoder
×欢迎使用Player FM
Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。